Ye
About 200 million people are suffering from diabetes worldwide and this figure is expected to increase to over 300 million by 2025. Over 90% is mature-onset or Type 2 diabetes. Type 2 diabetes has two fundamental metabolic perturbations: insulin resistance and inadequate insulin secretion.
Our studies focus on approaches for the reversal of insulin resistance, fatty liver and central obesity with use of pharmacological agents targeting key molecules crucial to insulin action. One of our major interests is the discovery and development of new anti-diabetic drugs from traditional Chinese medicines. We adopt a targeted approach starting with evaluation of traditional Chinese medicines, with criteria based on our expertise and the latest breakthroughs in the field, to select suitable candidates.
Subsequent research work involves cell-based and animal-based screening, assessment of efficacy in animal models, investigation of molecular mechanisms and identification of biological targets for potential drugs. Our translational research interacts closely with the Molecular Trafficking, Molecular Metabolism, Diabetes and Clinical Research Groups within the Diabetes and Obesity Program and external laboratories specializing in medicinal chemistry, drug design and synthesis and drug toxicity.
Staff
 Research OfficerTristan Iseli |
 Research AssistantXiaoyi (Conan) Zeng |
 PhD StudentRen (Helen) Luping |
See also:
